Vancomycin Infusion Versus Intermittent Dosing (VIVID)
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Intravenous vancomycin is considered first line therapy for serious methicillin-resistant
Staphylococcus aureus (MRSA) infections. The most common adverse effect of vancomycin is
nephrotoxicity. The risk of nephrotoxicity may depend on vancomycin dosing and chosen target.
Prior guidelines have recommended intermittent dosing and target trough level of 15-20mg/L.
Newer guidelines suggested targeting area under the curve over 24 hours (AUC) greater than
400. A feasible way of AUC guided dosing is continuous infusion targeting steady state
concentration of 17mg/L or greater. In prior observational studies, continuous infusion of
vancomycin was associated with a lower risk of nephrotoxicity. We will be conducting a
randomized controlled trial to compare continuous infusion and intermittent dosing of
intravenous vancomycin for serious MRSA infections in terms of nephrotoxicity.